ストックスクリーナーアプリを入手
1.795
0.55%
-0.015
前日終値:
$1.81
開ける：
$1.81
24時間の取引高:
390.31K
Relative Volume:
0.49
時価総額：
$76.35M
収益：
$55,200
当期純損益:
$-21.24M
株価収益率:
-3.0501
EPS:
-0.5885
ネットキャッシュフロー:
$-19.37M
1週間 パフォーマンス:
-11.33%
1か月 パフォーマンス:
+5.88%
6か月 パフォーマンス:
-25.31%
1年 パフォーマンス:
+12.50%
1日の値動き範囲:
$1.7201
$1.825
1週間の範囲:
$1.7201
$2.145
52週間の値動き範囲:
$1.41
$4.34
Gain Therapeutics Inc Stock (GANX) Company Profile
Compare GANX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.79 | 81.47M | 55,200 | -21.24M | -19.37M | -0.5885 |
VRTX
Vertex Pharmaceuticals Inc
|
520.10 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
669.53 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
924.65 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.22 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.25 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-06 | 開始されました | ROTH MKM | Buy |
| 2024-08-14 | 再開されました | Oppenheimer | Outperform |
| 2021-04-12 | 開始されました | BTIG Research | Buy |
| 2021-04-12 | 開始されました | Oppenheimer | Outperform |
Gain Therapeutics Inc (GANX) 最新ニュース
GANX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus
H.C. Wainwright reiterates Gain Therapeutics stock rating on FDA approval - Investing.com
Gain Therapeutics Buy Rating Reiterated as FDA Clears GT-02287 Phase 2; 12-Month $8 Price Target Maintained - TipRanks
Price to sales forward of Gain Therapeutics, Inc. – NASDAQ:GANX - TradingView
Number of shareholders of Gain Therapeutics, Inc. – NASDAQ:GANX - TradingView
Gain Therapeutics Receives FDA Clearance to Initiate Phase 2 Trial of GT-02287 for Parkinson’s Disease - Minichart
Stocks to Watch: AeroVironment, Concentrix, Gain Therapeutics, Praxis Precision Medicines - Moomoo
Why Is GANX Stock Rallying 22% After Hours? - Asianet Newsable
Gain Therapeutics advances GT-02287 into Phase 2 Parkinson’s trial - TipRanks
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Gain Therapeutics stock surges on FDA clearance for Parkinson’s drug By Investing.com - Investing.com India
Gain Therapeutics Gets US FDA Approval to Advance GT-02287 Into Phase 2 Study for Parkinson's Disease - marketscreener.com
Gain Therapeutics receives FDA clearance for Parkinson’s drug trial - Investing.com
Gain Therapeutics (GANX) wins FDA IND clearance to start GT-02287 Phase 2 Parkinson’s trial - Stock Titan
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease - The Manila Times
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 Into Phase 2 Development for Parkinson's Disease - Moomoo
FDA clears Gain Therapeutics drug GT-02287 for Phase 2 Parkinson’s trial - Stock Titan
Price to earnings forward of Gain Therapeutics, Inc. – NASDAQ:GANX - TradingView
Gain Therapeutics Inc (GANX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Gain Therapeutics, Inc. Announces 2026 Shareholder Vote Results and Emerging Growth Company Status (GANX) - Minichart
Gain Therapeutics, Inc. Actuals & Estimates (NASDAQ:GANX) - TradingView
Gain Therapeutics Shareholders Confirm Board and Auditor Choices - TipRanks
Gain Therapeutics (GANX) shareholders back board slate and Ernst & Young AG at 2026 meeting - Stock Titan
GANX Forecast — Price Target — Prediction for 2027 - TradingView
3 Clinical-Stage Biotech Stocks Worth Watching In Parkinson's Research - Sahm
Gain Therapeutics Inc (GANX) Institutional Confidence - TradingKey
Gain Therapeutics Inc (GANX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Gain Therapeutics Inc (GANX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Gain Therapeutics Inc (GANX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GAIN THERAPEUTICS INC (GANX) Stock Chart - ChartMill
Gain Therapeutics Inc (GANX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Gain Therapeutics Inc (GANX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Gain Therapeutics Inc (GANX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Gain Therapeutics Inc (GANX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Viking Therapeutics, Inc. (VKTX) gains as market dips: What you should know - MSN
Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know - Yahoo Finance
Gain Therapeutics Inc. (GANX) Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesRevenue Guidance Range - newsline.com
GANX Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit - The Manila Times
Biotech Gain Therapeutics joins H.C. Wainwright Neuro expert summit - Stock Titan
Bial Ends Development Of Parkinson’s Disease Drug After Phase IIb Fail - Citeline News & Insights
Niemann-Pick Type Pipeline Gains Momentum: 10+ Companies Lead - openPR.com
Which stocks are moving after the closing bell on Monday? - ChartMill
Dyne Therapeutics (DYN) investors double share authorization and approve all proposals - Stock Titan
TVTX: FILSPARI cements its role in rare kidney disease, with robust growth and pipeline innovation - TradingView
Tango Therapeutics Shares Surge 32% on Strong Clinical Momentum in Precision Oncology - International Business Times Australia
Monday's pre-market session: top gainers and losers - ChartMill
H.C. Wainwright Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
OPKO Health (OPK) Amends Partnership With Nicoya Therapeutics to Gain Equity Stake - Insider Monkey
Gain Therapeutics (GANX) price target increased by 11.76% to 7.75 - MSN
4 Biotech Stocks Investors Should Watch in 2026 - TradingView
Gain Therapeutics Inc (GANX) 財務データ
収益
当期純利益
現金流量
EPS
0.82%
0.85%
大文字化:
|
ボリューム (24 時間):